WHO recommends Oxford’s cheaper malaria vaccine
The low-dose R21 malaria vaccine has been recommended by WHO to ensure “sufficient vaccine supply” amid increasing demand.
Takeda withdraws cancer drug Exkivity after Phase III trial failure
Eli Lilly hit with FDA rejection for eczema drug
Sanofi and Janssen to develop vaccine candidate for E coli
Viatris announces plan to divest some businesses for $3.37bn
Novo Nordisk gains FDA approval for primary hyperoxaluria therapy
Analysis
View More
Themes
View MoreGenerative AI-focused biotech startup Evozyne raises $81m
The company’s algorithms put proteins through millions of years of simulated evolution to identify potential functional candidates.
More themes
Premium Insights
View MoreLeading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Discover premium insights powered by our properietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
ADDF invest in BrainScope for Alzheimer’s prediction biomarker
Market cap rebound by top 20 biopharmaceutical companies in Q2 2023
EMA CHMP recommends approval for Moderna’s updated Covid-19 vaccine
Corporate sustainability needs ESG standards and tools